Uridine adenosine tetraphosphate activation of the purinergic receptor P2Y enhances in vitro vascular calcification

Kidney International

Volumn 81, Issue 3, 2012, Pages 256-265

  Schuchardt, Mirjam ^a,b   Tölle, Markus ^a   Prüfer, Jasmin ^a,b   Prüfer, Nicole ^a   Huang, Tao ^a   Jankowski, Vera ^a   Jankowski, Joachim ^a   Zidek, Walter ^a   Van Der Giet, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

arteriosclerosis; cardiovascular; vascular calcification

Indexed keywords

ADENOSINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PURINE NUCLEOSIDE; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; TRANSCRIPTION FACTOR RUNX2; TRANSGELIN; UNCLASSIFIED DRUG; URIDINE ADENOSINE TETRAPHOSPHATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; CELL TRANSDIFFERENTIATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME PHOSPHORYLATION; EX VIVO STUDY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR RING; VASCULAR SMOOTH MUSCLE;

EID: 84856716922     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.326     Document Type: Article

References (54)

1. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009; 15: 405-416.
2. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938-2948. (Pubitemid 351787058)
3. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757.
4. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
5. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
6. Tyson KL, Reynolds JL, McNair R et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-494. (Pubitemid 36337227)
7. Giachelli CM. Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol 1999; 154: 671-675. (Pubitemid 29122585)
8. Levy RJ, Gundberg C, Scheinman R. The identification of the vitamin Kdependent bone protein osteocalcin as one of the gammacarboxyglutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. Atherosclerosis 1983; 46: 49-56. (Pubitemid 13180784)
9. Mori K, Shioi A, Jono S et al. Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 2112-2118. (Pubitemid 29422242)
10. Schoppet M, Al-Fakhri N, Franke FE et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-4112. (Pubitemid 39071519)
11. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567. (Pubitemid 39274370)
12. Nitta K, Akiba T, Uchida K et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303-309. (Pubitemid 36944438)
13. Nitta K, Akiba T, Uchida K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889. (Pubitemid 38961404)
14. Morony S, Tintut Y, Zhang Z et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117: 411-420.
15. Bennett BJ, Scatena M, Kirk EA et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 2006; 26: 2117-2124. (Pubitemid 44253797)
16. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268. (Pubitemid 28213402)
17. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216. (Pubitemid 351240642)
18. Neven E, Dauwe S, De Broe ME et al. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int 2007; 72: 574-581. (Pubitemid 47312790)
19. Wilkie AO, Tang Z, Elanko N et al. Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. Nat Genet 2000; 24: 387-390. (Pubitemid 30187438)
20. Igarashi M, Kamiya N, Hasegawa M et al. Inductive effects of dexamethasone on the gene expression of Cbfa1, Osterix and bone matrix proteins during differentiation of cultured primary rat osteoblasts. J Mol Histol 2004; 35: 3-10. (Pubitemid 40585329)
21. Di Virgilio F, Solini A. P2 receptors: new potential players in atherosclerosis. Br J Pharmacol 2002; 135: 831-842. (Pubitemid 34214442)
22. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-492. (Pubitemid 28477681)
23. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008; 4: 1-20.
24. Jankowski V, Tolle M, Vanholder R et al. Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. Nat Med 2005; 11: 223-227. (Pubitemid 40321359)
25. Tolle M, Schuchardt M, Wiedon A et al. Differential effects of uridine adenosine tetraphosphateon purinoceptors in the rat isolated perfused kidney. Br J Pharmacol 2010; 161: 530-540.
26. Bowler WB, Buckley KA, Gartland A et al. Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling. Bone 2001; 28: 507-512. (Pubitemid 32410002)
27. Schuchardt M, Prufer J, Prufer N et al. The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation. J Mol Med 2011; 89: 799-810.
28. Al-Aly Z, Shao J-S, Lai C-F et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-{alpha} dependent signals in diabetic Ldlr/mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-2596. (Pubitemid 350158910)
29. Jankowski V, van der Giet M, Mischak H et al. Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol 2009; 157: 1142-1153.
30. Jankowski V, Meyer AA, Schlattmann P et al. Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. Arterioscler Thromb Vasc Biol 2007; 27: 1776-1781. (Pubitemid 47207173)
31. Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci 2003; 24: 290-297. (Pubitemid 36725004)
32. Towler DA, Bidder M, Latifi T et al. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273: 30427-30434. (Pubitemid 28545516)
33. Moe SM, O'Neill KD, Duan D et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61: 638-647. (Pubitemid 34102607)
34. Speer MY, Yang HY, Brabb T et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741.
35. Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764. (Pubitemid 27516178)
36. Zheng H, Guo Z, Ma Q et al. Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 2004; 74: 194-203. (Pubitemid 38263863)
37. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154. (Pubitemid 34627872)
38. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867. (Pubitemid 41103395)
39. de Oca AM, Madueño JA, Martinez-Moreno JM et al. High-phosphateinduced calcification is related to SM22a promoter methylation in vascular smooth muscle cells. J Bone Miner Res 2010; 25: 1996-2005.
40. Wada T, McKee MD, Steitz S et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178. (Pubitemid 29070112)
41. Parker BD, Bauer DC, Ensrud KE et al. Association of osteocalcin and abdominal aortic calcification in older women: the study of osteoporotic fractures. Calcif Tissue Int 2010; 86: 185-191.
42. Proudfoot D, Skepper JN, Shanahan CM et al. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 1998; 18: 379-388. (Pubitemid 28125632)
43. Schor AM, Allen TD, Canfield AE et al. Pericytes derived from the retinal microvasculature undergo calcification in vitro. J Cell Sci 1990; 97(Pt 3): 449-461. (Pubitemid 20374486)
44. Giachelli CM, Bae N, Almeida M et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-1696. (Pubitemid 23304531)
45. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Yreceptor subtypes. Pharmacol Ther 2006; 110: 415-432.
46. Osman L, Chester AH, Amrani M et al. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation 2006; 114: I566-I572. (Pubitemid 44297209)
47. Wang L, Andersson M, Karlsson L et al. Increased mitogenic and decreased contractile P2 receptors in smooth muscle cells by shear stress in human vessels with intact endothelium. Arterioscler Thromb Vasc Biol 2003; 23: 1370-1376. (Pubitemid 36994524)
48. Xiao G, Jiang D, Thomas P et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 2000; 275: 4453-4459. (Pubitemid 30094689)
49. Soltoff SP, Avraham H, Avraham S et al. Activation of P2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. J Biol Chem 1998; 273: 2653-2660. (Pubitemid 28133908)
50. Franceschi RT, Ge C, Xiao G et al. Transcriptional regulation of osteoblasts. Ann N Y Acad Sci 2007; 1116: 196-207. (Pubitemid 350274351)
51. Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 2000; 219: 461-471.
52. Jankowski V, Gunthner T, Herget-Rosenthal S et al. Dinucleoside polyphosphates and uremia. Semin Dial 2009; 22: 396-399.
53. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-1339.
54. Shioi A, Nishizawa Y, Jono S et al. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995; 15: 2003-2009.